| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Special Report |
1 From the Departments of Radiology (A.L., R.L.G., M.M.) and Internal Medicine (G.D.) and the Institute of Internal Medicine and Pneumology (A.L., L.P.), University of Palermo, Ospedale V Cervello, Via Trabucco 180, 90146 Palermo, Italy, and the Institute of Medical Statistics and Biometry, University of Milan, Italy (A.M.). Received May 1, 1998; revision requested July 6; revision received August 26; accepted January 25, 1999. Address reprint requests to A.L.
PURPOSE: To compare the effects of transjugular intrahepatic portosystemic shunt (TIPS) creation with those of endoscopic treatment with or without propranolol administration (ie, conventional treatment) on recurrent bleeding, encephalopathy, and mortality by using meta-analysis of 11 published randomized clinical trials.
MATERIALS AND METHODS: Data from 11 relevant studies were retrieved by means of computerized and manual search. The combinability of the studies was assessed in terms of clinical and statistical criteria. Data were extracted on the basis of the intention-to-treat principle, and treatment effects were measured as risk differences between TIPS creation and conventional treatment. Pooled estimates were computed according to a random-effects model.
RESULTS: A total of 750 patients were included in 11 trials. No significant heterogeneity was found for any of the outcomes. Pooled risk differences were recurrent bleeding, -31% (95% CI, -39%, -23%); encephalopathy, +16% (95% CI, +10%, +22%); death due to all causes, +2% (95% CI, -4%, +9%); and death due to bleeding, -5% (95% CI, -11%, +6%). Clinically important complications occurred in 22% of patients and were associated with both treatments. TIPS dysfunction occurred in 55% of patients.
CONCLUSION: TIPS creation markedly reduces risk of rebleeding but increases risk of encephalopathy without affecting survival. Therefore, TIPS creation may not be the best first-choice therapy for prevention of recurrent variceal bleeding. Criteria for selection of candidates for TIPS creation should be assessed in future prospective studies.
Index terms: Liver, cirrhosis, 761.794 • Liver, hemorrhage, 761.458. 761.75 • Liver, interventional procedures, 761.1299 • Radiology and radiologists, outcomes studies • Shunts, portosystemic, 95.1268 • Varices, 71.75
This article has been cited by other articles:
|
|
 |
|
  S. Masson, H.A. Mardini, J.D. Rose, and C.O. Record Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience QJM, June 1, 2008; 101(6): 493 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dib, F. Oberti, and P. Cales Current management of the complications of portal hypertension: variceal bleeding and ascites. Can. Med. Assoc. J., May 9, 2006; 174(10): 1433 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Tripathi, H F Lui, A Helmy, K Dabos, E Forrest, A J Stanley, R Jalan, D N Redhead, and P C Hayes Randomised controlled trial of long term portographic follow up versus variceal band ligation following transjugular intrahepatic portosystemic stent shunt for preventing oesophageal variceal rebleeding Gut, March 1, 2004; 53(3): 431 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. T. Owen, E. A. Ryan, K. O'Kelly, J. R. T. Lakey, M. C. McCarthy, B. W. Paty, D. L. Bigam, N. M. Kneteman, G. S. Korbutt, R. V. Rajotte, et al. Percutaneous Transhepatic Pancreatic Islet Cell Transplantation in Type 1 Diabetes Mellitus: Radiologic Aspects Radiology, October 1, 2003; 229(1): 165 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Bellis, E Moitinho, J G Abraldes, M Graupera, J C Garcia-Pagan, J Rodes, and J Bosch Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction Gut, January 1, 2003; 52(1): 130 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Otal, T. Smayra, C. Bureau, J. M. Peron, V. Chabbert, P. Chemla, F. Joffre, J. P. Vinel, and H. Rousseau Preliminary Results of a New Expanded-Polytetrafluoroethylene--Covered Stent-Graft for Transjugular Intrahepatic Portosystemic Shunt Procedures Am. J. Roentgenol., January 1, 2002; 178(1): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Brancatelli, M. P. Federle, K. Pealer, and D. A. Geller Portal Venous Thrombosis or Sclerosis in Liver Transplantation Candidates: Preoperative CT Findings and Correlation with Surgical Procedure Radiology, August 1, 2001; 220(2): 321 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A K BURROUGHS, D W PATCH, R JALAN, and P C HAYES Management of variceal haemorrhage in cirrhotic patients Reply Gut, May 1, 2001; 48(5): 738a - 740. [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Helton, R. Maves, K. Wicks, and K. Johansen Transjugular Intrahepatic Portasystemic Shunt vs Surgical Shunt in Good-Risk Cirrhotic Patients: A Case-Control Comparison Arch Surg, January 1, 2001; 136(1): 17 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Daves The Liver and Vascular Surgery Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2000; 4(4): 275 - 288. [Abstract] [PDF]
|
|
